Lepu Biopharma Past Earnings Performance
Past criteria checks 0/6
Lepu Biopharma has been growing earnings at an average annual rate of 14%, while the Biotechs industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 119.5% per year.
Key information
14.0%
Earnings growth rate
33.7%
EPS growth rate
| Biotechs Industry Growth | 11.0% |
| Revenue growth rate | 119.5% |
| Return on equity | -3.4% |
| Net Margin | -9.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Lepu Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 225 | -22 | 130 | 458 |
| 30 Sep 23 | 197 | -254 | 119 | 492 |
| 30 Jun 23 | 169 | -487 | 109 | 525 |
| 31 Mar 23 | 92 | -588 | 125 | 525 |
| 31 Dec 22 | 16 | -689 | 141 | 524 |
| 30 Sep 22 | 8 | -766 | 152 | 567 |
| 30 Jun 22 | 0 | -843 | 163 | 609 |
| 31 Mar 22 | 0 | -927 | 160 | 700 |
| 31 Dec 21 | 0 | -1,011 | 156 | 791 |
| 31 Dec 20 | 0 | -582 | 94 | 354 |
Quality Earnings: 2157 is currently unprofitable.
Growing Profit Margin: 2157 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 2157 is unprofitable, but has reduced losses over the past 5 years at a rate of 14% per year.
Accelerating Growth: Unable to compare 2157's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 2157 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22.1%).
Return on Equity
High ROE: 2157 has a negative Return on Equity (-3.41%), as it is currently unprofitable.